Postmastectomy Radiation in HER-2 Positive Breast Cancer after Neoadjuvant Therapy: Secondary Analysis of Two Randomized Trials

被引：0
|
作者：
Zeidan, Y. [1 ]
Saifi, O. [2 ]
Bachir, B. [3 ]
Panoff, J. E. [4 ]
Poortmans, P. [5 ]
机构：
[1] Lynn Canc Inst, Baptist Hlth South Florida, Boca Raton, FL USA
[2] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL USA
[3] Amer Univ, Beirut Med Ctr, Beirut, Lebanon
[4] Baptist Hlth South Florida, Miami Canc Inst, Dept Radiat Oncol, Miami, FL USA
[5] lridium Kankernetwerk, Dept Radiat Oncol, Antwerp, Belgium
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2461
引用
收藏
页码：E216 / E216
页数：1
相关论文
共 50 条
  • [11] Treatment of HER-2 positive breast cancer
    Clavarezza, Matteo
    Venturini, Marco
    EJC SUPPLEMENTS, 2008, 6 (14): : 21 - 25
  • [12] Immunotherapy for HER-2 positive breast cancer
    Yang, Tingting
    Kang, Lihua
    Li, Dan
    Song, Yanqiu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [13] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [14] Efficacy and Safety of First-line Therapy in Patients with HER-2 positive Advanced Breast Cancer: A network Meta-analysis of Randomized Controlled Trials
    Wang, Junxiao
    Yu, Yushuai
    Zhang, Jie
    Song, Chuangui
    CANCER RESEARCH, 2024, 84 (09)
  • [15] Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
    Li, Fanfan
    Ju, Qian
    Gao, Cong
    Li, Jingjing
    Wang, Xiaolei
    Yan, Min
    Zhang, Liying
    Huang, Meiling
    Long, Qihe
    Jin, Xiangting
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [16] HER-2 therapy. HER-2/neu diagnostics in breast cancer
    Walter P Carney
    Kim Leitzel
    Suhail Ali
    Rainer Neumann
    Allan Lipton
    Breast Cancer Research, 9
  • [17] Analysis of drug resistance in HER-2 positive breast cancer.
    Lerma, N.
    Valenzuela, P.
    Parra, K.
    Becerril, C. L.
    Miramontes, I.
    Ramirez, E.
    Rodriguez, C.
    Francia, G.
    MOLECULAR BIOLOGY OF THE CELL, 2012, 23
  • [18] HER-2 as a Target for Breast Cancer Therapy
    Ignatiadis, Michail
    Desmedt, Christine
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    CLINICAL CANCER RESEARCH, 2009, 15 (06) : 1848 - 1852
  • [19] Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    ONCOLOGIST, 2006, 11 (08): : 857 - 867
  • [20] Pertuzumab as Part of Triple Therapy in HER-2 Positive Metastatic Breast Cancer
    Eslamian, G.
    AlHilali, M. N.
    Hameed, K.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E43 - E43
12345